Synaptogenix is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 5 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.85 |
|---|---|
| 52-week range | $3.27 - $11.48 |
| 50-day moving average | $3.93 |
| 200-day moving average | $4.89 |
| Wall St. target price | $14.00 |
| PE ratio | 0.3359 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $10.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.85 from 2024-09-12
| 1 week (2024-09-06) | -17.39% |
|---|---|
| 1 month (2024-08-14) | -19.72% |
| 3 months (2024-06-14) | -38.18% |
| 6 months (2024-03-14) | 1,483.33% |
| 1 year (2023-09-14) | 804.76% |
|---|---|
| 2 years (2022-09-14) | -64.38% |
| 3 years (2021-09-14) | 6.69 |
| 5 years (2019-09-10) | N/A |
Valuing Synaptogenix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Synaptogenix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Synaptogenix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Synaptogenix shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -13.82% |
| Return on equity TTM | -7.5% |
| Profit margin | 0% |
| Book value | $14.99 |
| Market Capitalization | $4.5 million |
TTM: trailing 12 months
We're not expecting Synaptogenix to pay a dividend over the next 12 months.
Synaptogenix's shares were split on a 1:25 basis on 4 April 2024. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synaptogenix shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Synaptogenix shares which in turn could have impacted Synaptogenix's share price.
Over the last 12 months, Synaptogenix's shares have ranged in value from as little as $3.2692 up to $11.475. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synaptogenix's is 1.461. This would suggest that Synaptogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U. S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.